Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
Calcitonin gene–related peptide (CGRP) dilates cerebral and dural vessels and may contribute to migraine, since cranial CGRP levels have been shown to be elevated in patients with migraine. In this randomized, controlled trial, patients with migraine had a higher rate of response to the CGRP-recepto...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2004-03, Vol.350 (11), p.1104-1110 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1110 |
|---|---|
| container_issue | 11 |
| container_start_page | 1104 |
| container_title | The New England journal of medicine |
| container_volume | 350 |
| creator | Olesen, Jes Diener, Hans-Christoph Husstedt, Ingo W Goadsby, Peter J Hall, David Meier, Ulrich Pollentier, Stephane Lesko, Lynna M |
| description | Calcitonin gene–related peptide (CGRP) dilates cerebral and dural vessels and may contribute to migraine, since cranial CGRP levels have been shown to be elevated in patients with migraine. In this randomized, controlled trial, patients with migraine had a higher rate of response to the CGRP-receptor antagonist BIBN 4096 BS than to placebo (66 percent vs. 27 percent).
A proof-of-concept study of a CGRP-receptor antagonist as an effective acute treatment for migraine.
Migraine is among the most common disorders, with a one-year prevalence of 12 percent.
1
,
2
According to the Global Burden of Disease Study conducted under the auspices of the World Health Organization, migraine is one of the leading causes of disability.
3
Although the availability of triptans — selective agonists of serotonin (5-hydroxytryptamine [5-HT]) receptors that activate 5-HT
1B
and 5-HT
1D
(5-HT
1B/1D
) receptors — has greatly improved the acute treatment of migraine, many patients have no response to triptans, complete pain relief is the exception rather than the rule, and their vasoconstrictive properties cause concern among doctors and . . . |
| doi_str_mv | 10.1056/NEJMoa030505 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17306013</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>578621521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5145-bc9adeb1cd545421013d6ffa39d0a9ca98a6cecd59efd09a346ec2ce366d135f3</originalsourceid><addsrcrecordid>eNpt0MtuEzEUBmALgdrQdse6shCwYqg9vjReJlEprXpTKevRiX3cTjTjCbZnwY534A37JBglUqsKb3yk8-m39RPyjrMvnCl9dHVyfjkAE0wx9YpMuBKikpLp12TCWD2t5LERu-RtSitWDpdmh-xyVQY-FRPiF9DZNg-hDfQUAz7-_nOLHWR09AbXuXVIb9GWaYh0FjLcF5kynZ_Nr6hkRtP5d-rLLj8gndkxI72LCLnHkOng6WV7H6ENuE_eeOgSHmzvPfLj68nd4lt1cX16tphdVFZxqaqlNeBwya1TUsmaMy6c9h6EcQyMBTMFbbFsDXrHDAip0dYWhdaOC-XFHvm0yV3H4eeIKTd9myx2HQQcxtTwY8F0SS3w_Qu4GsYYyt-auhZGylqxgj5vkI1DShF9s45tD_FXw1nzr_zmefmFH24zx2WP7glv2y7g4xZAstD5CMG26ZlTUhs5Le7DxvV9agKu-v-_9xcDbpby</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223944250</pqid></control><display><type>article</type><title>Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Olesen, Jes ; Diener, Hans-Christoph ; Husstedt, Ingo W ; Goadsby, Peter J ; Hall, David ; Meier, Ulrich ; Pollentier, Stephane ; Lesko, Lynna M</creator><creatorcontrib>Olesen, Jes ; Diener, Hans-Christoph ; Husstedt, Ingo W ; Goadsby, Peter J ; Hall, David ; Meier, Ulrich ; Pollentier, Stephane ; Lesko, Lynna M ; BIBN 4096 BS Clinical Proof of Concept Study Group</creatorcontrib><description>Calcitonin gene–related peptide (CGRP) dilates cerebral and dural vessels and may contribute to migraine, since cranial CGRP levels have been shown to be elevated in patients with migraine. In this randomized, controlled trial, patients with migraine had a higher rate of response to the CGRP-receptor antagonist BIBN 4096 BS than to placebo (66 percent vs. 27 percent).
A proof-of-concept study of a CGRP-receptor antagonist as an effective acute treatment for migraine.
Migraine is among the most common disorders, with a one-year prevalence of 12 percent.
1
,
2
According to the Global Burden of Disease Study conducted under the auspices of the World Health Organization, migraine is one of the leading causes of disability.
3
Although the availability of triptans — selective agonists of serotonin (5-hydroxytryptamine [5-HT]) receptors that activate 5-HT
1B
and 5-HT
1D
(5-HT
1B/1D
) receptors — has greatly improved the acute treatment of migraine, many patients have no response to triptans, complete pain relief is the exception rather than the rule, and their vasoconstrictive properties cause concern among doctors and . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa030505</identifier><identifier>PMID: 15014183</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Acute Disease ; Adult ; Biological and medical sciences ; Calcitonin Gene-Related Peptide Receptor Antagonists ; Clinical outcomes ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug therapy ; Female ; General aspects ; Humans ; Male ; Medical sciences ; Medical treatment ; Middle Aged ; Migraine ; Migraine Disorders - drug therapy ; Neurology ; Piperazines ; Piperidines - adverse effects ; Piperidines - therapeutic use ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; Time Factors ; Vascular diseases and vascular malformations of the nervous system</subject><ispartof>The New England journal of medicine, 2004-03, Vol.350 (11), p.1104-1110</ispartof><rights>Copyright © 2004 Massachusetts Medical Society. All rights reserved.</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 Massachusetts Medical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5145-bc9adeb1cd545421013d6ffa39d0a9ca98a6cecd59efd09a346ec2ce366d135f3</citedby><cites>FETCH-LOGICAL-c5145-bc9adeb1cd545421013d6ffa39d0a9ca98a6cecd59efd09a346ec2ce366d135f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa030505$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/223944250?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2757,2758,26102,27923,27924,52381,54063,64384,64386,64388,72240</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15546948$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15014183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Olesen, Jes</creatorcontrib><creatorcontrib>Diener, Hans-Christoph</creatorcontrib><creatorcontrib>Husstedt, Ingo W</creatorcontrib><creatorcontrib>Goadsby, Peter J</creatorcontrib><creatorcontrib>Hall, David</creatorcontrib><creatorcontrib>Meier, Ulrich</creatorcontrib><creatorcontrib>Pollentier, Stephane</creatorcontrib><creatorcontrib>Lesko, Lynna M</creatorcontrib><creatorcontrib>BIBN 4096 BS Clinical Proof of Concept Study Group</creatorcontrib><title>Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Calcitonin gene–related peptide (CGRP) dilates cerebral and dural vessels and may contribute to migraine, since cranial CGRP levels have been shown to be elevated in patients with migraine. In this randomized, controlled trial, patients with migraine had a higher rate of response to the CGRP-receptor antagonist BIBN 4096 BS than to placebo (66 percent vs. 27 percent).
A proof-of-concept study of a CGRP-receptor antagonist as an effective acute treatment for migraine.
Migraine is among the most common disorders, with a one-year prevalence of 12 percent.
1
,
2
According to the Global Burden of Disease Study conducted under the auspices of the World Health Organization, migraine is one of the leading causes of disability.
3
Although the availability of triptans — selective agonists of serotonin (5-hydroxytryptamine [5-HT]) receptors that activate 5-HT
1B
and 5-HT
1D
(5-HT
1B/1D
) receptors — has greatly improved the acute treatment of migraine, many patients have no response to triptans, complete pain relief is the exception rather than the rule, and their vasoconstrictive properties cause concern among doctors and . . .</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Calcitonin Gene-Related Peptide Receptor Antagonists</subject><subject>Clinical outcomes</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Female</subject><subject>General aspects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>Neurology</subject><subject>Piperazines</subject><subject>Piperidines - adverse effects</subject><subject>Piperidines - therapeutic use</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>Time Factors</subject><subject>Vascular diseases and vascular malformations of the nervous system</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0MtuEzEUBmALgdrQdse6shCwYqg9vjReJlEprXpTKevRiX3cTjTjCbZnwY534A37JBglUqsKb3yk8-m39RPyjrMvnCl9dHVyfjkAE0wx9YpMuBKikpLp12TCWD2t5LERu-RtSitWDpdmh-xyVQY-FRPiF9DZNg-hDfQUAz7-_nOLHWR09AbXuXVIb9GWaYh0FjLcF5kynZ_Nr6hkRtP5d-rLLj8gndkxI72LCLnHkOng6WV7H6ENuE_eeOgSHmzvPfLj68nd4lt1cX16tphdVFZxqaqlNeBwya1TUsmaMy6c9h6EcQyMBTMFbbFsDXrHDAip0dYWhdaOC-XFHvm0yV3H4eeIKTd9myx2HQQcxtTwY8F0SS3w_Qu4GsYYyt-auhZGylqxgj5vkI1DShF9s45tD_FXw1nzr_zmefmFH24zx2WP7glv2y7g4xZAstD5CMG26ZlTUhs5Le7DxvV9agKu-v-_9xcDbpby</recordid><startdate>20040311</startdate><enddate>20040311</enddate><creator>Olesen, Jes</creator><creator>Diener, Hans-Christoph</creator><creator>Husstedt, Ingo W</creator><creator>Goadsby, Peter J</creator><creator>Hall, David</creator><creator>Meier, Ulrich</creator><creator>Pollentier, Stephane</creator><creator>Lesko, Lynna M</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7TK</scope></search><sort><creationdate>20040311</creationdate><title>Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine</title><author>Olesen, Jes ; Diener, Hans-Christoph ; Husstedt, Ingo W ; Goadsby, Peter J ; Hall, David ; Meier, Ulrich ; Pollentier, Stephane ; Lesko, Lynna M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5145-bc9adeb1cd545421013d6ffa39d0a9ca98a6cecd59efd09a346ec2ce366d135f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Calcitonin Gene-Related Peptide Receptor Antagonists</topic><topic>Clinical outcomes</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Female</topic><topic>General aspects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>Neurology</topic><topic>Piperazines</topic><topic>Piperidines - adverse effects</topic><topic>Piperidines - therapeutic use</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>Time Factors</topic><topic>Vascular diseases and vascular malformations of the nervous system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Olesen, Jes</creatorcontrib><creatorcontrib>Diener, Hans-Christoph</creatorcontrib><creatorcontrib>Husstedt, Ingo W</creatorcontrib><creatorcontrib>Goadsby, Peter J</creatorcontrib><creatorcontrib>Hall, David</creatorcontrib><creatorcontrib>Meier, Ulrich</creatorcontrib><creatorcontrib>Pollentier, Stephane</creatorcontrib><creatorcontrib>Lesko, Lynna M</creatorcontrib><creatorcontrib>BIBN 4096 BS Clinical Proof of Concept Study Group</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Neurosciences Abstracts</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Olesen, Jes</au><au>Diener, Hans-Christoph</au><au>Husstedt, Ingo W</au><au>Goadsby, Peter J</au><au>Hall, David</au><au>Meier, Ulrich</au><au>Pollentier, Stephane</au><au>Lesko, Lynna M</au><aucorp>BIBN 4096 BS Clinical Proof of Concept Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2004-03-11</date><risdate>2004</risdate><volume>350</volume><issue>11</issue><spage>1104</spage><epage>1110</epage><pages>1104-1110</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Calcitonin gene–related peptide (CGRP) dilates cerebral and dural vessels and may contribute to migraine, since cranial CGRP levels have been shown to be elevated in patients with migraine. In this randomized, controlled trial, patients with migraine had a higher rate of response to the CGRP-receptor antagonist BIBN 4096 BS than to placebo (66 percent vs. 27 percent).
A proof-of-concept study of a CGRP-receptor antagonist as an effective acute treatment for migraine.
Migraine is among the most common disorders, with a one-year prevalence of 12 percent.
1
,
2
According to the Global Burden of Disease Study conducted under the auspices of the World Health Organization, migraine is one of the leading causes of disability.
3
Although the availability of triptans — selective agonists of serotonin (5-hydroxytryptamine [5-HT]) receptors that activate 5-HT
1B
and 5-HT
1D
(5-HT
1B/1D
) receptors — has greatly improved the acute treatment of migraine, many patients have no response to triptans, complete pain relief is the exception rather than the rule, and their vasoconstrictive properties cause concern among doctors and . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>15014183</pmid><doi>10.1056/NEJMoa030505</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2004-03, Vol.350 (11), p.1104-1110 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17306013 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Acute Disease Adult Biological and medical sciences Calcitonin Gene-Related Peptide Receptor Antagonists Clinical outcomes Dose-Response Relationship, Drug Double-Blind Method Drug therapy Female General aspects Humans Male Medical sciences Medical treatment Middle Aged Migraine Migraine Disorders - drug therapy Neurology Piperazines Piperidines - adverse effects Piperidines - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use Time Factors Vascular diseases and vascular malformations of the nervous system |
| title | Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T15%3A09%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Calcitonin%20Gene%E2%80%93Related%20Peptide%20Receptor%20Antagonist%20BIBN%204096%20BS%20for%20the%20Acute%20Treatment%20of%20Migraine&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Olesen,%20Jes&rft.aucorp=BIBN%204096%20BS%20Clinical%20Proof%20of%20Concept%20Study%20Group&rft.date=2004-03-11&rft.volume=350&rft.issue=11&rft.spage=1104&rft.epage=1110&rft.pages=1104-1110&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJMoa030505&rft_dat=%3Cproquest_cross%3E578621521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223944250&rft_id=info:pmid/15014183&rfr_iscdi=true |